Results 11 to 20 of about 1,054 (155)

Short-term prevention of perimenstrual migraine with rimegepant [PDF]

The Journal of Headache and Pain
Background Menstrually-related migraine (MRM) affects approximately 31–52% of women with migraine and are characterized by increased frequency, severity, and reduced response to conventional therapy during the perimenstrual window. Traditional short-term
Florian Frank, Alois Schiefecker, Katharina Kaltseis, Michael Eller, Gregor Broessner   +4 more
doaj   +4 more sources

Treating Menière’s disease with rimegepant

Swiss Medical Weekly
A recent hypothesis states that Menière’s disease is caused by inappropriate expression, i.e. enhanced release of the neurotransmitter calcitonin gene-related peptide.
Stefan C. A. Hegemann, Angela Schell
doaj   +3 more sources

Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis [PDF]

The Journal of Headache and Pain
Objective To determine the efficacy and tolerability of a single 75 mg oral dose of rimegepant compared with placebo for the acute treatment of migraine attacks in adults.
Melissa Istoc, Basit A. Chaudhry, Rune H. Christensen, Haidar M. Al-Khazali, Messoud Ashina, William K. Karlsson, Håkan Ashina   +6 more
doaj   +2 more sources

Rimegepant 75 mg for Acute Treatment of Migraine Is Associated With Significant Reduction in Monthly Migraine Days: Results From a Long-Term, Open-Label Study

Cephalalgia Reports, 2022
Background: Rimegepant, a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, is approved for the acute and preventive treatment of migraine. We hypothesized that intermittent CGRP receptor blockade with rimegepant 75 mg acute
Karissa M. Johnston, Lauren C Powell, Robert Croop   +2 more
exaly   +2 more sources

Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma [PDF]

BMC Oral Health
Background Pain is the most frequent complication in patients with oral squamous cell carcinoma (OSCC) and is associated with poor prognosis. Calcitonin gene–related peptide (CGRP), abundantly expressed in sensory neurons, has been implicated in multiple
Mingtao Chen, Yibo Guo, Zheqi Liu, Chengzhong Lin, Yang Wang, Xi Yang, Tong Ji, Chenping Zhang, Yu Zhang   +8 more
doaj   +2 more sources

Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study [PDF]

Frontiers in Neurology
BackgroundRimegepant, an oral calcitonin gene-related peptide receptor antagonist approved for both acute and preventive migraine treatment, demonstrates efficacy in clinical trials, but real-world evidence remains limited.
Hamza Khan, Muhammad Saqib Khan, Sheraz Khan, Fang Liu, Quan Feng, Irfan Ahmad, Ge Tan   +6 more
doaj   +2 more sources

Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study [PDF]

The Journal of Headache and Pain
Background Vestibular migraine (VM) is the second most common cause of episodic vertigo worldwide, yet effective therapeutic options remain limited. This study aimed to assess the clinical effectiveness of rimegepant in patients with VM.
Jinyan Shao, Jingxin Fu, Mengting Zhou, Zewei Ren, Longxiang Li, Lili Gao, Yuhui Xia, Zexian Zhao, Mengna Yang, Jiahuan He, Siyuan Xue, Guoming Wang, Jiahui He, Kaiming Liu   +13 more
doaj   +2 more sources

Post-marketing safety concerns with rimegepant based on a pharmacovigilance study

The Journal of Headache and Pain
Purpose This study aimed to comprehensively assess the safety of rimegepant administration in real-world clinical settings. Methods Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning the second quarter of 2020 ...
Jia-Ling Hu, Jing-Ying Wu, Shan Xu, Shi-Yan Qian, Cheng Jiang, Guo-Qing Zheng   +5 more
doaj   +3 more sources

Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics

The Journal of Headache and Pain
Background Rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, is the first drug within its class approved for both acute and preventive treatment of migraine. This study examines its uptake in Denmark.
Lanfranco Pellesi, Thien Phu Do, Martin Thomsen Ernst, Jesper Hallas, Anton Pottegård   +4 more
doaj   +3 more sources

Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine Is Associated With a Reduction in the Utilization of Select Analgesics and Antiemetics

Journal of Pain Research
Terence Fullerton,1 Glenn Pixton2 1Internal Medicine and Infectious Disease, Pfizer Research and Development, Pfizer Inc., Groton, CT, USA; 2Statistics, Pfizer Inc., Groton, CT, USACorrespondence: Terence Fullerton, Internal Medicine and Infectious ...
Terence Fullerton
exaly   +2 more sources